BACKGROUND & AIMS: The IMAgINE 1 study (NCT00409682) evaluated the safety and
efficacy of adalimumab double-blind maintenance dosing regimens following open-label …

Background & Aims: The REACH study evaluated the safety and efficacy of infliximab in
children with moderately to severely active Crohn's disease. Methods: Patients (n= 112) with …

OBJECTIVES: Adalimumab, an anti-tumor necrosis factor immunoglobulin-1 antibody, is
increasingly being reported as a potential treatment option for children with moderate-to …

Objective: Assess long-term effects of maintenance infliximab therapy in children with
moderately-to-severely active Crohn's disease. Research design and methods: One …

Background Adalimumab, a fully human monoclonal antibody (IgG1κ) to tumor necrosis
factor, has shown benefit in the treatment of inflammatory bowel disease. The purpose of this …

Background Infliximab therapy has short-term benefits in children with moderate-to-severe
Crohn's disease (CD). We assessed the long-term outcome of infliximab maintenance …

Background Infliximab (IFX) is efficacious in inducing remission in severe forms of pediatric
Crohn's disease (CD). Adult studies indicate that IFX is also safe and well tolerated as …

OBJECTIVES: The aim of this study was to assess the efficacy and safety of a single infusion
of infliximab in the treatment of pediatric Crohn's disease (CD). METHODS: A total of 21 …

OBJECTIVES: Tumor necrosis factor-α plays a central role in chronic intestinal inflammation
of Crohn's disease. Targeting this cytokine with the chimeric monoclonal antibody infliximab …

Background & Aims: This study evaluated the efficacy and safety of adalimumab, a fully
human, anti–tumor necrosis factor monoclonal antibody administered subcutaneously, in the …